Under the theme of “Inheritance & Innovation, Digital-Intelligence Empowerment — Building a New Paradigm for High-Quality Development of Andrology”, the conference focuses on new technologies and clinical research in male sexual dysfunction, prostate diseases and other fields — closely aligned with the technology direction of WBL LIPUS. the booth will present the related devices and clinical application solutions.

▲ Figure 2 · Exhibition floor plan: the red box marks the WBL booth

▲ Figure 3 · Rendering of the WBL booth

Live product demonstrations and technical exchanges will be available during the conference. Colleagues are welcome to visit the WBL Booth for a hands-on experience and discussion.

WBL LIPUS (Low-Intensity Pulsed Ultrasound) is a non-invasive acoustic therapy that delivers pulsed ultrasound at defined parameters to target tissue. The treatment requires no surgery and no systemic medication, offering a new physical-therapy option for ED.

▲ Figure 4 · Mechanism of LIPUS: vascular repair and nerve regeneration

In January 2024, the Chinese Expert Consensus on LIPUS Treatment of Erectile Dysfunction was officially published (Chinese Journal of Andrology, Vol. 38, No. 1), and LIPUS therapy was incorporated into the consensus. From joint theoretical innovation and animal research with UC San Francisco since 2012, to multi-center clinical validation in China, and further to consensus inclusion and CE certification, the translational pathway of LIPUS is clearly documented.

PATHWAY / From Mild-Moderate to Severe ED

ED is graded by the IIEF-5 score into mild (17–21), mild-to-moderate (12–16), moderate (8–11) and severe (5–7). It is a progressively developing disease, often regarded as a “

▲ Figure 5 · ED grading and the LIPUS evidence gradient

The 2024 consensus outlines a stratified approach: mild-to-moderate ED may be treated with LIPUS alone; patients with an inadequate response to oral medication may combine LIPUS with their therapy(8 sessions per course), subject to evaluation by the treating physician. From the 2016 multi-center study in mild-moderate ED to the 2026 prospective study in severe ED, the evidence base of LIPUS has been building step by step along this pathway.

SEVERE / Severe ED: A New Treatment Option

Severe ED has long been a therapeutic challenge in andrology. In 2026, the prospective study by the urology-andrology team of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, entitled "Low-intensity pulsed ultrasound for severe erectile dysfunction: A prospective study with 3-year follow-up", was accepted by the international urology journal Current Urology. The study used precisely the WBL-ED Low-Intensity Pulsed Ultrasound Therapy Device — patients with severe ED can also be treated with LIPUS. Conducted from September 2020 to December 2021, the study enrolled 52 patients with severe ED, of whom 43 completed the standard course (2 sessions per week for 4 weeks, 8 in total) and the week-8 evaluation.

At week 8, the IIEF-EF score of the 43 subjects rose from a baseline of 6.98 to 14.53 (a mean gain of 7.56 points, p<0.001); 22 subjects (51.2%) reached the ≥7-point minimal clinically important difference (MCID) threshold; the median erection hardness score (EHS) improved from grade 1 to grade 3, and the proportion with morning erections rose from 54.8% to 81.0%; post-treatment pain VAS scores were all 0, with no adverse events recorded. In a telephone follow-up about 3 years later, 65% of the 20 reachable subjects reported erections maintained to completion of intercourse, and 70% perceived their erectile function as improved over baseline.

The authors also note rigorously that this was a single-arm, exploratory observational study with attrition during long-term follow-up, and the results need further validation in larger-sample, randomized controlled studies. Together with the 2019 multi-center randomized double-blind study in mild-moderate ED and the 2022 randomized clinical study comparing 3 vs. 2 sessions per week, the evidence base of LIPUS is extending from mild-moderate to severe ED, and from short-term observation to long-term follow-up. Whether LIPUS therapy is appropriate should still be determined by a professional andrologist through comprehensive evaluation and an individualized plan.

▲ Figure 6 · First page of the severe-ED prospective study, Current Urology (2026)

References: Chinese Expert Consensus on LIPUS Treatment of Erectile Dysfunction (2024); WBL five-center multi-center clinical study (2016); severe-ED prospective study with 3-year follow-up, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Current Urology (2026).

WBL maintains long-term collaboration with leading experts at home and abroad: the LIPUS technology was advocated by Academician Guo Yinglu, and the company has carried out long-term industry-academia-research cooperation with the team of Professor Tom Lue at UC San Francisco (UCSF) and Professor Xin Zhongcheng; through its "Ninth Muscle" science-popularization platform, WBL promotes physician and patient education, industrial collaboration and international exchange. The product won the 2025 IDEA Design Award, and the devices have entered many tertiary and prefecture-level hospitals in China as well as King Chulalongkorn Memorial Hospital in Thailand.

▲ CCTV "Sci-Tech China" program coverage

The poster hall is one of the key academic exchange sections of this conference, and it includes multiple studies on WBL LIPUS — covering action mechanisms, dose parameters, different patient populations and combination therapies, LIPUS is becoming a hot topic in andrology research and clinical practice. The following titles are selected from the conference poster directory:

From mechanisms to dosing, from diabetic ED to venous ED, from combination therapy to nursing management — these titles outline the research landscape of LIPUS at this conference. You are welcome to visit Booth A07 for in-depth discussion.

Note: the titles above are quoted from the conference poster directory; the actual posters on site shall prevail.

During the conference, WBL will showcase devices covering detection, assessment and treatment. Here is a preview of the five exhibits:

This conference is an annual academic gala for andrology and an important occasion for disciplinary innovation and talent development. WBL looks forward to meeting colleagues from across the country in Jinan — experiencing the innovative LIPUS devices at the WBL booth, exploring clinical applications and discipline development together, and joining hands to advance a new paradigm for the high-quality development of andrology, contributing wisdom and strength to patients' health and well-being.

VENUE / Venue & Dates

Shandong Building

▲ Figure 7 · Location of the Shandong Building: No. 2-1 Ma'anshan Road, Jinan, west of Qianfo Hill Park